



Carcinoma of the gastroesophageal junction in Chinese patients

Citation

Huang, Qin. 2012. "Carcinoma of the Gastroesophageal Junction in Chinese Patients." World Journal of Gastroenterology 18 (48): 7134. doi:10.3748/wjg.v18.i48.7134.

Permanent link

<http://nrs.harvard.edu/urn-3:HUL.InstRepos:41542754>

Terms of Use

This article was downloaded from Harvard University's DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at <http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA>

Share Your Story

The Harvard community has made this article openly available.
Please share how this access benefits you. [Submit a story](#).

[Accessibility](#)

Carcinoma of the gastroesophageal junction in Chinese patients

Qin Huang

Qin Huang, Department of Pathology, Nanjing Drum Tower Hospital, Nanjing 020008, Jiangsu Province, China

Qin Huang, Department of Pathology and Laboratory Medicine, Veterans Affairs Boston Healthcare System and Harvard Medical School, 1400 VFW Parkway, West Roxbury, MA 02132, United States

Author contributions: Huang Q designed, executed the studies, and wrote the manuscript.

Supported by Science and Technology Development Project of the Nanjing City in China, No. ZKX05013, No. ZKX07011; a special grant from the Nanjing Drum Tower Hospital in Nanjing, China

Correspondence to: Qin Huang, MD, PhD, Department of Pathology and Laboratory Medicine, Veterans Affairs Boston Healthcare System and Harvard Medical School, 1400 VFW Parkway, West Roxbury, MA 02132, United States. qinhuang0122@gmail.com

Telephone: +1-857-2035020 Fax: +1-857-2035623

Received: August 27, 2012 Revised: October 25, 2012

Accepted: November 6, 2012

Published online: December 28, 2012

Abstract

Carcinoma of the gastroesophageal junction (GEJ) is defined as carcinoma that crosses the GEJ line, irrespective of where the tumor epicenter is located. This group of cancer is rare but controversial. Based on study results from the majority of epidemiologic and clinicopathologic investigations carried out in Western countries, this cancer is believed to arise from Barrett's esophagus (BE) and includes both distal esophageal and proximal gastric carcinomas because of similar characteristics in epidemiology, clinicopathology, and molecular pathobiology in relation to BE. As such, the most recent American Joint Committee on Cancer staging manual requires staging all GEJ carcinomas with the rule for esophageal adenocarcinoma (EA). This mandate has been challenged recently by the data from several studies carried out mainly in Chinese patients. The emerging evidence derived

from those studies suggests: (1) both BE and EA are uncommon in the Chinese population; (2) almost all GEJ cancers in Chinese arise in the proximal stomach and show the features of proximal gastric cancer, not those of EA; (3) application of the new cancer staging rule to GEJ cancer of Chinese patients cannot stratify patients' prognosis effectively; and (4) prognostic factors of GEJ cancer in Chinese are similar, but not identical, to those of EA. In conclusion, the recent evidence suggests that GEJ cancer in Chinese shows distinct clinicopathologic characteristics that are different from EA. Further investigations in molecular pathology may help illustrate the underlying pathogenesis mechanisms of this cancer in Chinese patients and better manage patients with this fatal disease.

© 2012 Baishideng. All rights reserved.

Key words: Esophagus; Stomach; Cancer; Gastroesophageal junction; Staging; Barrett's esophagus

Peer reviewers: Kenneth E McColl, Professor, Institute of Cardiovascular and Medical Sciences, University of Glasgow, 44 Church Street, Glasgow G11 6NT, Scotland, United Kingdom; Zhiheng Pei, MD, PhD, Assistant Professor, Department of Pathology and Medicine, New York University School of Medicine, Department of Veterans Affairs, New York Harbor Healthcare System, 6001W, 423 East 23rd Street, New York City, NY 10010, United States

Huang Q. Carcinoma of the gastroesophageal junction in Chinese patients. *World J Gastroenterol* 2012; 18(48): 7134-7140 Available from: URL: <http://www.wjgnet.com/1007-9327/full/v18/i48/7134.htm> DOI: <http://dx.doi.org/10.3748/wjg.v18.i48.7134>

INTRODUCTION

Carcinomas of the gastroesophageal junction (GEJ) is defined by the World Health Organization (WHO) as tu-

mors “that cross the oesophagogastric junction... regardless of where the bulk of the tumours lies”^[1]. Therefore, this cancer may arise from the distal esophagus, grow downward, cross the GEJ line, and invade the proximal stomach, or originate from the proximal stomach, grow upward, and invade the distal esophagus. For better surgical management of patients, Siewert and Stein classify this cancer into 3 types: Type I cancer shows epicenter in the distal esophagus 1-5 cm above the GEJ; Type III cancer centers within the proximal stomach 2-5 cm below the GEJ; and Type II tumor straddles the GEJ within a 3-cm longitudinal spread of 1 cm above and 2 cm below the GEJ^[2-4].

At present, the underlying mechanisms of tumorigenesis for this uncommon cancer are poorly understood^[5-7]. Several investigators from Western countries believe adenocarcinoma of the proximal stomach, i.e., gastric cardiac carcinoma, to be similar, or even identical, to Barrett’s esophagus (BE)-associated distal esophageal adenocarcinoma (EA) on the basis of comparable characteristics in epidemiology^[8-14], clinical presentations^[15-23], molecular pathobiology^[24], and histopathology^[17,25-27]. This notion has been adopted by the American Joint Committee on Cancer that published the 7th edition of the cancer staging manual (AJCC 7) in 2009, requiring staging all GEJ cancers with the rule for EA^[28].

Over the past decade, a growing body of evidence has been published on epidemiology^[29-31] and clinicopathology^[32-36] of GEJ carcinoma in Chinese patients with the standardized criteria. The emerging data suggest that GEJ carcinoma in Chinese is heterogeneous in histology and shows clinicopathologic features different from those of EA. This article critically reviews the most recent evidence on this fatal cancer in Chinese patients with the intention to promote clinical research and to better manage Chinese patients with this cancer.

BE AND DISTAL EA REMAIN SCARCE IN CHINESE

Several recent population-based studies using the BE diagnostic criteria of the American Gastroenterology Association show a very low frequency of BE in the Chinese population^[29,37-43]. In 2008, Tseng *et al*^[29] reported a frequency of 0.28% of patients with columnar-lined esophagus out of 19 810 consecutive subjects at annual health check-up with upper endoscopy. By histology, among those with columnar-lined esophagus only 12 subjects had intestinal metaplasia and were qualified as BE patients, rendering a prevalence rate of 0.06% in the general population^[29]. In referral patients for upper endoscopy, Kuo *et al*^[30] reported only 1.8% of BE cases from 735 consecutive subjects. Similar results were also described in another upper endoscopy study of 5179 patients with a prevalence rate of BE at 1% and 0.35% for referral and screening cases at annual health check-up. These results have been repeatedly confirmed by several other endoscopy studies^[40-42,44,45]. In addition to this very

low prevalence rate, BE in most Chinese subjects is in the short- or ultra-short segment, i.e., shorter than 3 cm in the longitudinal length^[40,46-49]. Chen *et al*^[49] studied 4120 qualified BE cases in a meta analysis of 308 original research articles published over the period from 1997 to 2007. They reported overwhelming BE cases (78%) in the short-segment and most in tongue- and island-like endoscopic mucosal lesion patterns (78%). The long segment BE is infrequent and has not been reported in Chinese women. In a histopathology study of distal esophageal mucosa in patients with proximal gastric carcinoma, Sun *et al*^[50] reported the finding of columnar-lined esophagus in up to 65% of the cases, 97% of which was confined within 1 cm above the GEJ line.

Similarly, EA remains rare in the Chinese population^[51-57], unlike that in patients from the West where the incidence of EA has been rapidly rising in the most recent years and EA has outnumbered esophageal squamous cell carcinoma^[58,59]. A population-based epidemiology study carried out in Taiwan over a 25-year period from 1979 to 2003 showed a steadily increasing trend for esophageal squamous cell carcinoma but not for EA^[60]. In another study in Hong Kong, investigators even reported a decreasing trend for EA over a 20-year period from 1984 to 2003^[31]. Among 10 751 new esophageal cancer cases reported to the Hong Kong Cancer Registry, the number of EA cases decreased from 224 in 1984 to 131 in 1998 to 2003, a dramatic drop of over 40% in incidence^[31].

By histopathology, investigators from a major tertiary medical center in Taiwan did not find a single case of EA over a 20-year period from 1987 to 2007^[35]. Most recently, armed with the WHO diagnostic criteria^[1] and the recently defined histological definition of the GEJ line^[61,62], pathologists in Nanjing studied histopathologic features of consecutive 206 radical resections of tumors in the distal esophagus in a homogenous Chinese population and identified only 2 (1%) cases of true EA^[34]. In that study, esophageal squamous cell carcinoma stays predominant^[34].

These clinical study data suggest that BE-related diseases including EA remain uncommon in the Chinese population in the most recent years and may not be the source of their GEJ cancer^[63].

CLINICOPATHOLOGIC FEATURES ARE NOT THOSE OF EA

To answer the question as to where GEJ cancer in Chinese patients arises and what clinicopathologic differences in this cancer between Chinese and Westerners could be, a recent comparison study on clinicopathologic features of GEJ cancer with the WHO diagnostic criteria was conducted between Chinese patients treated in Nanjing, China, and American patients treated in Boston, the United States^[33]. The researchers reported remarkable differences in almost all clinicopathologic characteristics of GEJ cancer between these two different ethnic

patient populations. In general, Chinese patients were 6-year younger, more in the female gender, and presented with tumors 1.5 cm larger in size. Their tumors were all centered in the proximal stomach and heterogeneous in histology with substantial proportions of the cases showing uncommon types such as adenosquamous cell carcinoma, neuroendocrine carcinoma, and pancreatic acinar-like adenocarcinoma^[32,33,64]. In contrast in American patients, almost all tumors were centered in the distal esophagus and homogeneous as EA in histology^[33]. As to the peri-tumor mucosal diseases in Chinese patients, although distal esophageal columnar metaplasia (14%) and dysplasia (0) were uncommon or absent, chronic gastritis (81%) and *Helicobacter pylori* (*H. pylori*) infection (35%) were widespread. Again, in a sharp contrast, distal esophageal columnar metaplasia (87%) and dysplasia (67%) in the Americans were overwhelming; but chronic gastritis (24%) and *H. pylori* infection (19%) were uncommon in the uninvolved proximal gastric mucosa^[33]. The results suggest that GEJ cancer in American patients is indeed associated with BE and shows the clinicopathologic features of EA^[25,65-68]. In contrast, GEJ cancer in Chinese is in fact primary proximal gastric cancer and different from EA.

Despite the fact that the results of this single comparison study confirm the rationale on the AJCC 7 classification of this cancer as EA in American patients, the new AJCC 7 mandate for classification of all GEJ cancers as EA may be questionable and ineffective in Chinese patients.

APPLICATION OF STAGING RULES ON EA CANNOT EFFECTIVELY PREDICT SURVIVAL IN CHINESE PATIENTS

The updated AJCC 7 staging guideline classifies all GEJ cancers as EA and requires staging these tumors as esophageal cancer^[28]. The validity and effectiveness of this new mandate has been found problematic in Chinese patients. Researchers in Nanjing, China, investigated 142 cases of GEJ cancer and reported inferior stratification of survival prediction to survival stratification with the staging rule for gastric cancer, especially for pN and summary pIII C stages, when these cases were staged with the scheme for EA based on the AJCC 7 new guideline^[69]. They reported that the pN stage was more predictive in survival than the pT, which is consistent with the features of gastric cancer. In addition, they described a useful survival predictive value for celiac nodal disease and the lymph node ratio in patients with this cancer. In contrast, using the staging guideline for EA, they discovered illogical patient survival characteristics. For example, the Kaplan-Meier curves for patients staged at pIII A predicted erroneously better survival than those staged at pIA and pIIB. Moreover, the survival curves also crossed in the cases staged at pII B and pIII B, indicating the existence of intra-group hetero-

geneity. Importantly, even with the staging scheme for gastric cancer, the survival curves for patients with this cancer were not distinctive and showed incorrectly better survival prediction for patients staged at p I B and p II B than those at p I A and p II A. Interestingly enough, patients staged at pN3b had the 5-year survival rate worse than those with pM1 and pIV diseases^[69]. These observations, taken along with the group clustering in p II A, p II B, p III A, and p III B, illustrate a poor discriminatory ability of the new AJCC 7 staging rule for this cancer in Chinese^[70,71].

One of intriguing facts in Chinese patients with this cancer is that despite the larger tumor size and higher overall pathologic stage with stage pIII-IV in 70% of cases, the 5-year survival rate for patients with stage pIII tumors is significantly better in Chinese than in American patients^[69]. A similar result for patients with proximal gastric cancer staged at pIII has been reported previously in an epidemiology study on the data derived from the Surveillance, Epidemiology, and End Results database^[11]. In that study, although the overall patient survival curves are almost identical between EA and proximal gastric cancer groups, a distinct separation in survival curves between these two groups is demonstrated for patients with pIII diseases; importantly, the patients with proximal gastric cancer and staged at pIII show a much better survival trend than those with EA^[11]. These results demonstrate a unique characteristic for proximal gastric cancer, which is distinctly different from that of EA^[69].

The aforementioned preliminary data suggest that GEJ cancer in Chinese cannot be staged predicatively as EA with the new AJCC 7 guideline, as confirmed in a recent South Korean study^[72]. Even staged with the rules for gastric cancer, these cases cannot be monotonically stratified for prognosis prediction^[69], suggesting the existence of discrete pathobiological characteristics that set this cancer apart from EA and less characteristically from conventional gastric cancer^[73]. Regardless, the study of GEJ cancer in Chinese patients treated in Nanjing is limited by a relatively small sample size, advanced pT3 disease in the majority of the cases, and a lack of consistent surgical lymphadenectomy procedure carried out in all cases^[69]. Further investigation with defined criteria and a larger sample size is needed to validate those interesting results.

PROGNOSTIC FACTORS AND SIRT1 GENE EXPRESSION

In the most recent reports on prognostic factors of EA with a large sample size, well-defined clinicopathologic characteristics, and robust follow-up from Western countries, the worse 5-year disease-specific prognostic factors are found to be associated with higher pT, pN stages, advanced age over 76 years, signet-ring cell histology, poor tumor differentiation, and extra-nodal diseases^[74-77]. These prognostic factors for EA have been reported to

be similar, but not identical, to those in Chinese patients with GEJ cancer in recent publications^[78-80]. However, because of the limited number of reports on this issue, the results are a bit inconsistent. For instance, in one report with 514 surgical resection cases of GEJ cancer at a major medical center in China, tumor gross and histology type, stage, vascular invasion, and extent of surgical resection were found to be significant prognostic factors^[78]. In another detailed clinicopathology study report^[79], patient age over 70 years, tumor size larger than 8 cm, poor differentiation, the number of positive lymph nodes over 16, and advanced summary pathology stage were shown to be associated with worse outcomes. In contrast, lymphovascular invasion, which is associated with worse survival in EA^[80], is not shown to be a significant prognostic factor. Interestingly, celiac nodal metastasis and the lymph node ratio for the number of lymph node retrieved and nodal disease are reported to be significant prognostic factors^[81-83]. The investigators further reported that the ratio of the number of positive nodes identified *v*s the number of total lymph nodes evaluated was related to significantly worse overall survival^[79]. Furthermore, the patient survival rate becomes significantly worse for the lymph node ratio over 0.2, compared to the cases with negative nodal disease. The relative risk of worse prognosis for the ratio over 0.4 or 0.5 is 37-fold or 75-fold^[79]. This powerful prognostic prediction by the lymph node ratio is very practical in clinical settings where nodal dissection by individual surgeons and nodal retrieval by pathologists vary and a unified nodal dissection protocol is not universally executed. This simple, easy-to-use, and objective prognostic indicator in gastric cancer has been repeatedly confirmed by many other investigators around the world^[84-91].

Advanced age has been proven to be one of independent worse prognostic factors in GEJ cancer^[74,75,79]. This may result from genetic abnormalities in aging associated genes such as Sirt1, which is a recently discovered, aging-related histone deacetylase involved in regulation of multiple critical steps of stress responses, nutrient metabolism, and aging through deacetylation of a variety of subcellular molecules such as p53, forkhead transcription factors, PGC-1 α , NF- κ B, Ku70, and histones^[92-97]. An increasing body of evidence in molecular biology suggests a complex role for Sirt1 to play in tumorigenesis^[96-101]. Feng *et al*^[102] are the first to use tissue microarray and immunohistochemical methods to investigate the Sirt1 gene expression in proximal gastric cancer including GEJ cancer in Chinese patients. They reported that compared to normal controls, Sirt1 gene expression was significantly higher in a subgroup of GEJ cancer cases, which was significantly associated lymph node metastasis, higher pathologic stages, and worse survival prognosis with significantly lower 1- and 3-year survival rates (80% and 49%), compared to the Sirt1-negative cancer patient groups (89% and 71%), suggesting a prognostic predictive value for this molecule in patients with this cancer. It should be interesting to know how Sirt1 plays

in the initiation and progression of GEJ cancer in Chinese patients.

CONCLUSION

GEJ cancer is uncommon but poorly understood for its natural history, pathogenesis mechanisms, and prognosis. An increasing body of evidence accumulated in recent years suggests that GEJ cancer in Chinese patients arises mainly in the proximal stomach associated with chronic gastritis and shows a heterogeneous histology pattern. This cancer is distinctly different from EA and cannot be accurately stratified with the scheme for EA, as required by the updated AJCC 7 cancer staging guideline for patient survival prognosis prediction. Although the new AJCC 7 staging rule for gastric cancer may be used for this cancer, there exists considerable heterogeneity and indistinctive survival characteristics, suggesting the possibility of a distinct disease entity for this cancer.

REFERENCES

- 1 **Odze RD**, Flejou JF, Boffetta P, Hofler H, Montgomery E, Spechler SJ. Adenocarcinoma of the oesophagogastric junction. In: Bosman FT, Carneiro F, Hruban RH, Theise ND, editors. WHO Classification of Tumours of the Digestive System, World Health Organization Classification of Tumours, Lyon: IARC Press, 2010: 39-44
- 2 **Siewert JR**, Stein HJ. Classification of adenocarcinoma of the oesophagogastric junction. *Br J Surg* 1998; **85**: 1457-1459
- 3 **Siewert JR**, Stein HJ, Feith M. Adenocarcinoma of the esophago-gastric junction. *Scand J Surg* 2006; **95**: 260-269
- 4 **Rüdiger Siewert J**, Feith M, Werner M, Stein HJ. Adenocarcinoma of the esophagogastric junction: results of surgical therapy based on anatomical/topographic classification in 1,002 consecutive patients. *Ann Surg* 2000; **232**: 353-361
- 5 **McColl KE**, Going JJ. Aetiology and classification of adenocarcinoma of the gastro-oesophageal junction/cardia. *Gut* 2010; **59**: 282-284
- 6 **Schneider PM**. Preface. The Siewert Lesson for Adenocarcinomas of the esophagogastric junction: a plea for an order in a complex disease. *Recent Results Cancer Res* 2010; **182**: vii-viii
- 7 **von Rahden BH**, Feith M, Stein HJ. Carcinoma of the cardia: classification as esophageal or gastric cancer? *Int J Colorectal Dis* 2005; **20**: 89-93
- 8 **Blot WJ**, Devesa SS, Kneller RW, Fraumeni JF. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. *JAMA* 1991; **265**: 1287-1289
- 9 **Crane SJ**, Richard Locke G, Harmsen WS, Diehl NN, Zinsmeister AR, Joseph Melton L, Romero Y, Talley NJ. The changing incidence of oesophageal and gastric adenocarcinoma by anatomic sub-site. *Aliment Pharmacol Ther* 2007; **25**: 447-453
- 10 **Vial M**, Grande L, Pera M. Epidemiology of adenocarcinoma of the esophagus, gastric cardia, and upper gastric third. *Recent Results Cancer Res* 2010; **182**: 1-17
- 11 **Whitson BA**, Groth SS, Li Z, Kratzke RA, Maddaus MA. Survival of patients with distal esophageal and gastric cardia tumors: a population-based analysis of gastroesophageal junction carcinomas. *J Thorac Cardiovasc Surg* 2010; **139**: 43-48
- 12 **Pera M**, Cameron AJ, Trastek VF, Carpenter HA, Zinsmeister AR. Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction. *Gastroenterology* 1993; **104**: 510-513

- 13 **Demeester SR.** Epidemiology and biology of esophageal cancer. *Gastrointest Cancer Res* 2009; **3**: S2-S5
- 14 **Keeney S, Bauer TL.** Epidemiology of adenocarcinoma of the esophagogastric junction. *Surg Oncol Clin N Am* 2006; **15**: 687-696
- 15 **Chow WH, Blot WJ, Vaughan TL, Risch HA, Gammon MD, Stanford JL, Dubrow R, Schoenberg JB, Mayne ST, Farrow DC, Ahsan H, West AB, Rotterdam H, Niwa S, Fraumeni JF.** Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia. *J Natl Cancer Inst* 1998; **90**: 150-155
- 16 **Portale G, Peters JH, Hagen JA, Demeester SR, Gandamihardja TA, Tharavej C, Hsieh CC, Demeester TR.** Comparison of the clinical and histological characteristics and survival of distal esophageal-gastroesophageal junction adenocarcinoma in patients with and without Barrett mucosa. *Arch Surg* 2005; **140**: 570-574; discussion 574-575
- 17 **Leers JM, DeMeester SR, Chan N, Ayazi S, Oezcelik A, Abate E, Banki F, Lipham JC, Hagen JA, DeMeester TR.** Clinical characteristics, biologic behavior, and survival after esophagectomy are similar for adenocarcinoma of the gastroesophageal junction and the distal esophagus. *J Thorac Cardiovasc Surg* 2009; **138**: 594-602; discussion 601-602
- 18 **Rice TW, Rusch VW, Ishwaran H, Blackstone EH.** Cancer of the esophagus and esophagogastric junction: data-driven staging for the seventh edition of the American Joint Committee on Cancer/International Union Against Cancer Cancer Staging Manuals. *Cancer* 2010; **116**: 3763-3773
- 19 **Lagergren J, Bergström R, Lindgren A, Nyrén O.** Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. *N Engl J Med* 1999; **340**: 825-831
- 20 **Chow WH, Blot WJ, Vaughan TL, Risch HA, Gammon MD, Stanford JL, Dubrow R, Schoenberg JB, Mayne ST, Farrow DC, Ahsan H, West AB, Rotterdam H, Niwa S, Fraumeni JF Jr.** Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia. *J Natl Cancer Inst* 1998; **90**: 150-155
- 21 **Cameron AJ, Lomboy CT, Pera M, Carpenter HA.** Adenocarcinoma of the esophagogastric junction and Barrett's esophagus. *Gastroenterology* 1995; **109**: 1541-1546
- 22 **Marsman WA, Tytgat GN, ten Kate FJ, van Lanschot JJ.** Differences and similarities of adenocarcinomas of the esophagus and esophagogastric junction. *J Surg Oncol* 2005; **92**: 160-168
- 23 **Dolan K, Morris AI, Gosney JR, Field JK, Sutton R.** Three different subsite classification systems for carcinomas in the proximity of the GEJ, but is it all one disease? *J Gastroenterol Hepatol* 2004; **19**: 24-30
- 24 **Wijnhoven BP, Siersema PD, Hop WC, van Dekken H, Tilanus HW.** Adenocarcinomas of the distal oesophagus and gastric cardia are one clinical entity. Rotterdam Oesophageal Tumour Study Group. *Br J Surg* 1999; **86**: 529-535
- 25 **Hamilton SR, Smith RR, Cameron JL.** Prevalence and characteristics of Barrett esophagus in patients with adenocarcinoma of the esophagus or esophagogastric junction. *Hum Pathol* 1988; **19**: 942-948
- 26 **Ruol A, Parenti A, Zaninotto G, Merigliano S, Costantini M, Cagol M, Alfieri R, Bonavina L, Peracchia A, Ancona E.** Intestinal metaplasia is the probable common precursor of adenocarcinoma in Barrett esophagus and adenocarcinoma of the gastric cardia. *Cancer* 2000; **88**: 2520-2528
- 27 **Chandrasoma P, Wickramasinghe K, Ma Y, DeMeester T.** Adenocarcinomas of the distal esophagus and "gastric cardia" are predominantly esophageal carcinomas. *Am J Surg Pathol* 2007; **31**: 569-575
- 28 **American Joint Committee on Cancer.** AJCC Cancer Staging Manual. Chapter 10, Esophagus and Esophagogastric Junction. 7th ed. New York: Springer, 2009: 129-144
- 29 **Tseng PH, Lee YC, Chiu HM, Huang SP, Liao WC, Chen CC, Wang HP, Wu MS, Lin JT.** Prevalence and clinical characteristics of Barrett's esophagus in a Chinese general population. *J Clin Gastroenterol* 2008; **42**: 1074-1079
- 30 **Kuo CJ, Lin CH, Liu NJ, Wu RC, Tang JH, Cheng CL.** Frequency and risk factors for Barrett's esophagus in Taiwanese patients: a prospective study in a tertiary referral center. *Dig Dis Sci* 2010; **55**: 1337-1343
- 31 **Yee YK, Cheung TK, Chan AO, Yuen MF, Wong BC.** Decreasing trend of esophageal adenocarcinoma in Hong Kong. *Cancer Epidemiol Biomarkers Prev* 2007; **16**: 2637-2640
- 32 **Huang Q, Zhang LH.** The histopathologic spectrum of carcinomas involving the gastroesophageal junction in the Chinese. *Int J Surg Pathol* 2007; **15**: 38-52
- 33 **Huang Q, Fan X, Agoston AT, Feng A, Yu H, Lauwers G, Zhang L, Odze RD.** Comparison of gastro-oesophageal junction carcinomas in Chinese versus American patients. *Histopathology* 2011; **59**: 188-197
- 34 **Huang Q, Shi J, Sun Q, Fan X, Feng A, Wu H, Zhou Q, Yu C, Mashimo H, Lauwers GY.** Distal esophageal carcinomas in Chinese patients vary widely in histopathology, but adenocarcinomas remain rare. *Hum Pathol* 2012; **43**: 2138-2148
- 35 **Fang WL, Wu CW, Chen JH, Lo SS, Hsieh MC, Shen KH, Hsu WH, Li AF, Lui WY.** Esophagogastric junction adenocarcinoma according to Siewert classification in Taiwan. *Ann Surg Oncol* 2009; **16**: 3237-3244
- 36 **Wang LD, Zheng S, Zheng ZY, Casson AG.** Primary adenocarcinomas of lower esophagus, esophagogastric junction and gastric cardia: in special reference to China. *World J Gastroenterol* 2003; **9**: 1156-1164
- 37 **Wu JC.** Gastroesophageal reflux disease: an Asian perspective. *J Gastroenterol Hepatol* 2008; **23**: 1785-1793
- 38 **Lam KD, Phan JT, Garcia RT, Trinh H, Nguyen H, Nguyen K, Triadafilopoulos G, Vutien P, Nguyen L, Nguyen MH.** Low proportion of Barrett's esophagus in Asian Americans. *Am J Gastroenterol* 2008; **103**: 1625-1630
- 39 **Wong WM, Lam SK, Hui WM, Lai KC, Chan CK, Hu WH, Xia HH, Hui CK, Yuen MF, Chan AO, Wong BC.** Long-term prospective follow-up of endoscopic oesophagitis in southern Chinese--prevalence and spectrum of the disease. *Aliment Pharmacol Ther* 2002; **16**: 2037-2042
- 40 **Lu XS, Wang CW.** The research and character of clinical and endoscopic of Barrett's esophagus and the value of Lugol's staining in diagnosis of it. Shantou, China: The Master Degree Thesis Shantou University Medical School, 2010: 1-45
- 41 **Zou XP, Zhang M, Zhang XQ, Yu CC, Zhuge YZ, Zhang LH, Fan XS.** Prevalence of Barrett's Esophagus in Chinese Mainland: Four Years Prospective Study. *J Clin Gastroent* 2011; **45**: 1
- 42 **Wong WM, Lam SK, Hui WM, Lai KC, Chan CK, Hu WH, Xia HH, Hui CK, Yuen MF, Chan AO, Wong BC.** Long-term prospective follow-up of endoscopic oesophagitis in southern Chinese--prevalence and spectrum of the disease. *Aliment Pharmacol Ther* 2002; **16**: 2037-2042
- 43 **Kamangar F, Qiao YL, Blaser MJ, Sun XD, Katki H, Fan JH, Perez-Perez GI, Abnet CC, Zhao P, Mark SD, Taylor PR, Dawsey SM.** Helicobacter pylori and oesophageal and gastric cancers in a prospective study in China. *Br J Cancer* 2007; **96**: 172-176
- 44 **Guo HM, He HW.** Analysis for the endoscopic characteristics in Barrett's esophagus and the relationship between Barrett's esophagus and reflux esophagitis. *Hebei Med J* 2010; **32**: 2818-2820
- 45 **He M, Yang LL.** Clinical and Pathological Features of Barrett Esophagus. *China Mod Doc* 2010; **48**: 25-26
- 46 **Chang CY, Lee YC, Lee CT, Tu CH, Hwang JC, Chiang H, Tai CM, Chiang TH, Wu MS, Lin JT.** The application of Prague C and M criteria in the diagnosis of Barrett's esophagus in an ethnic Chinese population. *Am J Gastroenterol* 2009; **104**: 13-20
- 47 **Peng S, Cui Y, Xiao YL, Xiong LS, Hu PJ, Li CJ, Chen MH.** Prevalence of erosive esophagitis and Barrett's esophagus in the adult Chinese population. *Endoscopy* 2009; **41**: 1011-1017

- 48 **Xiong LS**, Cui Y, Wang JP, Wang JH, Xue L, Hu PJ, Chen MH. Prevalence and risk factors of Barrett's esophagus in patients undergoing endoscopy for upper gastrointestinal symptoms. *J Dig Dis* 2010; **11**: 83-87
- 49 **Chen X**, Zhu LR, Hou XH. The characteristics of Barrett's esophagus: an analysis of 4120 cases in China. *Dis Esophagus* 2009; **22**: 348-353
- 50 **Sun Q**, Huang Q, Feng AN, Fan XS, Wu HY, Mashimo H, Zhou Q, Chen J, Lauwers GY. Columnar-lined esophagus in Chinese patients with proximal gastric carcinomas. *J Dig Dis* 2013; **14**: 22-28
- 51 **Lam KY**, Dickens P, Loke SL, Fok M, Ma L, Wong J. Squamous cell carcinoma of the oesophagus with mucin-secreting component (muco-epidermoid carcinoma and adenosquamous carcinoma): a clinicopathologic study and a review of literature. *Eur J Surg Oncol* 1994; **20**: 25-31
- 52 **Chang SS**, Lu CL, Chao JY, Chao Y, Yen SH, Wang SS, Chang FY, Lee SD. Unchanging trend of adenocarcinoma of the esophagus and gastric cardia in Taiwan: a 15-year experience in a single center. *Dig Dis Sci* 2002; **47**: 735-740
- 53 **Fan YJ**, Song X, Li JL, Li XM, Liu B, Wang R, Fan ZM, Wang LD. Esophageal and gastric cardia cancers on 4238 Chinese patients residing in municipal and rural regions: a histopathological comparison during 24-year period. *World J Surg* 2008; **32**: 1980-1988
- 54 **Fan YJ**, Song X, Li JL, Li XM, Liu B, Wang R, Fan ZM, Wang LD. Esophageal and gastric cardia cancers on 4238 Chinese patients residing in municipal and rural regions: a histopathological comparison during 24-year period. *World J Surg* 2008; **32**: 1980-1988
- 55 **Chang D**, Wang TY, Wei JC, Song JX, Jiao GG. [Surgical treatment of primary esophageal adenocarcinoma]. *Zhonghua Waike Zazhi* 2007; **45**: 681-683
- 56 **Guo W**, Blot WJ, Li JY, Taylor PR, Liu BQ, Wang W, Wu YP, Zheng W, Dawsey SM, Li B. A nested case-control study of oesophageal and stomach cancers in the Linxian nutrition intervention trial. *Int J Epidemiol* 1994; **23**: 444-450
- 57 **Li JY**, Ershow AG, Chen ZJ, Wacholder S, Li GY, Guo W, Li B, Blot WJ. A case-control study of cancer of the esophagus and gastric cardia in Linxian. *Int J Cancer* 1989; **43**: 755-761
- 58 **Vizcaino AP**, Moreno V, Lambert R, Parkin DM. Time trends incidence of both major histologic types of esophageal carcinomas in selected countries, 1973-1995. *Int J Cancer* 2002; **99**: 860-868
- 59 **Shaheen NJ**. Advances in Barrett's esophagus and esophageal adenocarcinoma. *Gastroenterology* 2005; **128**: 1554-1566
- 60 **Lu CL**, Lang HC, Luo JC, Liu CC, Lin HC, Chang FY, Lee SD. Increasing trend of the incidence of esophageal squamous cell carcinoma, but not adenocarcinoma, in Taiwan. *Cancer Causes Control* 2010; **21**: 269-274
- 61 **Srivastava A**, Odze RD, Lauwers GY, Redston M, Antonioli DA, Glickman JN. Morphologic features are useful in distinguishing Barrett esophagus from carditis with intestinal metaplasia. *Am J Surg Pathol* 2007; **31**: 1733-1741
- 62 **Huang Q**. Definition of the esophagogastric junction: a critical mini review. *Arch Pathol Lab Med* 2011; **135**: 384-389
- 63 **Huang Q**, Fang DC, Yu CG, Zhang J, Chen MH. Barrett's esophagus-related diseases remain uncommon in China. *J Dig Dis* 2011; **12**: 420-427
- 64 **Huang Q**, Gold JS, Shi J, Fan X, Wu H, Feng A, Zhou Q. Pancreatic acinar-like adenocarcinoma of the proximal stomach invading the esophagus. *Hum Pathol* 2012; **43**: 911-920
- 65 **Haggitt RC**. Barrett's esophagus, dysplasia, and adenocarcinoma. *Hum Pathol* 1994; **25**: 982-993
- 66 **Kalish RJ**, Clancy PE, Orringer MB, Appelman HD. Clinical, epidemiologic, and morphologic comparison between adenocarcinomas arising in Barrett's esophageal mucosa and in the gastric cardia. *Gastroenterology* 1984; **86**: 461-467
- 67 **Smith RR**, Hamilton SR, Boitnott JK, Rogers EL. The spectrum of carcinoma arising in Barrett's esophagus. A clinicopathologic study of 26 patients. *Am J Surg Pathol* 1984; **8**: 563-573
- 68 **Cameron AJ**, Souto EO, Smyrk TC. Small adenocarcinomas of the esophagogastric junction: association with intestinal metaplasia and dysplasia. *Am J Gastroenterol* 2002; **97**: 1375-1380
- 69 **Huang Q**, Shi J, Feng A, Fan X, Zhang L, Mashimo H, Cohen D, Lauwers G. Gastric cardiac carcinomas involving the esophagus are more adequately staged as gastric cancers by the 7th edition of the American Joint Commission on Cancer Staging System. *Mod Pathol* 2011; **24**: 138-146
- 70 **Xu D**, Huang Y, Geng Q, Guan Y, Li Y, Wang W, Yuan S, Sun X, Chen Y, Li W, Zhou Z, Zhan Y. Effect of lymph node number on survival of patients with lymph node-negative gastric cancer according to the 7th edition UICC TNM system. *PLoS One* 2012; **7**: e38681
- 71 **Sun Z**, Wang ZN, Zhu Z, Xu YY, Xu Y, Huang BJ, Zhu GL, Xu HM. Evaluation of the seventh edition of American Joint Committee on Cancer TNM staging system for gastric cancer: results from a Chinese monoinstitutional study. *Ann Surg Oncol* 2012; **19**: 1918-1927
- 72 **Suh YS**, Han DS, Kong SH, Lee HJ, Kim YT, Kim WH, Lee KU, Yang HK. Should adenocarcinoma of the esophagogastric junction be classified as esophageal cancer? A comparative analysis according to the seventh AJCC TNM classification. *Ann Surg* 2012; **255**: 908-915
- 73 **Gertler R**, Stein HJ, Loos M, Langer R, Friess H, Feith M. How to classify adenocarcinomas of the esophagogastric junction: as esophageal or gastric cancer? *Am J Surg Pathol* 2011; **35**: 1512-1522
- 74 **Yoon HH**, Khan M, Shi Q, Cassivi SD, Wu TT, Quevedo JF, Burch PA, Sinicrpe FA, Diasio RB. The prognostic value of clinical and pathologic factors in esophageal adenocarcinoma: a mayo cohort of 796 patients with extended follow-up after surgical resection. *Mayo Clin Proc* 2010; **85**: 1080-1089
- 75 **Talsma K**, van Hagen P, Grotenhuis BA, Steyerberg EW, Tilanus HW, van Lanschot JJ, Wijnhoven BP. Comparison of the 6th and 7th Editions of the UICC-AJCC TNM Classification for Esophageal Cancer. *Ann Surg Oncol* 2012; **19**: 2142-2148
- 76 **Reynolds JV**, Ravi N, Muldoon C, Larkin JO, Rowley S, O'Byrne K, Hollywood D, O'Toole D. Differential pathologic variables and outcomes across the spectrum of adenocarcinoma of the esophagogastric junction. *World J Surg* 2010; **34**: 2821-2829
- 77 **Lagarde SM**, ten Kate FJ, Reitsma JB, Busch OR, van Lanschot JJ. Prognostic factors in adenocarcinoma of the esophagus or gastroesophageal junction. *J Clin Oncol* 2006; **24**: 4347-4355
- 78 **Yang H**, Wu AW, Li ZY, Bu ZD, Zhang LH, Wu XJ, Zong XL, Li SX, Shan F, Yang Y, Ji JF. [Surgical treatment results and prognostic analysis of 514 cases with gastroesophageal junction carcinoma]. *Zhonghua Waike Zazhi* 2010; **48**:
- 79 **Zhang YF**, Shi J, Yu HP, Feng AN, Fan XS, Lauwers GY, Mashimo H, Gold JS, Chen G, Huang Q. Factors predicting survival in patients with proximal gastric carcinoma involving the esophagus. *World J Gastroenterol* 2012; **18**: 3602-3609
- 80 **Barbour AP**, Jones M, Brown I, Gotley DC, Martin I, Thomas J, Clouston A, Smithers BM. Risk stratification for early esophageal adenocarcinoma: analysis of lymphatic spread and prognostic factors. *Ann Surg Oncol* 2010; **17**: 2494-2502
- 81 **Schomas DA**, Quevedo JF, Donahue JM, Nichols FC, Romero Y, Miller RC. The prognostic importance of pathologically involved celiac node metastases in node-positive patients with carcinoma of the distal esophagus or gastroesophageal junction: a surgical series from the Mayo Clinic. *Dis Esophagus* 2010; **23**: 232-239
- 82 **Yu JW**, Wu JG, Zheng LH, Zhang B, Ni XC, Li XQ, Jiang BJ. Influencing factors and clinical significance of the metastatic

- lymph nodes ratio in gastric adenocarcinoma. *J Exp Clin Cancer Res* 2009; **28**: 55
- 83 **Wang W**, Li YF, Sun XW, Chen YB, Li W, Xu DZ, Guan XX, Huang CY, Zhan YQ, Zhou ZW. Prognosis of 980 patients with gastric cancer after surgical resection. *Chin J Cancer* 2010; **29**: 923-930
- 84 **Siewert JR**, Böttcher K, Stein HJ, Roder JD. Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. *Ann Surg* 1998; **228**: 449-461
- 85 **Bando E**, Yonemura Y, Taniguchi K, Fushida S, Fujimura T, Miwa K. Outcome of ratio of lymph node metastasis in gastric carcinoma. *Ann Surg Oncol* 2002; **9**: 775-784
- 86 **Nitti D**, Marchet A, Olivieri M, Ambrosi A, Mencarelli R, Belluco C, Lise M. Ratio between metastatic and examined lymph nodes is an independent prognostic factor after D2 resection for gastric cancer: analysis of a large European monoinstitutional experience. *Ann Surg Oncol* 2003; **10**: 1077-1085
- 87 **Saito H**, Fukumoto Y, Osaki T, Yamada Y, Fukuda K, Tatebe S, Tsujitani S, Ikeguchi M. Prognostic significance of the ratio between metastatic and dissected lymph nodes (n ratio) in patients with advanced gastric cancer. *J Surg Oncol* 2008; **97**: 132-135
- 88 **Santiago JR**, Osorio J, Gutierrez I, Perez N, Mufioz E, Veloso E, Marco C. Prognostic usefulness of lymph node ratio in understaged gastric cancer. *Hepatogastroenterology* 2009; **56**: 1557-1561
- 89 **Chen S**, Zhao BW, Li YF, Feng XY, Sun XW, Li W, Zhou ZW, Zhan YQ, Qian CN, Chen YB. The prognostic value of harvested lymph nodes and the metastatic lymph node ratio for gastric cancer patients: results of a study of 1,101 patients. *PLoS One* 2012; **7**: e49424
- 90 **Hyung WJ**, Noh SH, Yoo CH, Huh JH, Shin DW, Lah KH, Lee JH, Choi SH, Min JS. Prognostic significance of metastatic lymph node ratio in T3 gastric cancer. *World J Surg* 2002; **26**: 323-329
- 91 **Latengbaolide A**, Lin D, Li Y, Xu H, Chen J, Wang B, Liu C, Lu P. Lymph Node Ratio Is an Independent Prognostic Factor in Gastric Cancer After Curative Resection (R0) Regardless of the Examined Number of Lymph Nodes. *Am J Clin Oncol* 2012 Apr 27; Epub ahead of print
- 92 **Li K**, Luo J. The role of SIRT1 in tumorigenesis. *N Am J Med Sci* (Boston) 2011; **4**: 104-106
- 93 **Jung-Hynes B**, Nihal M, Zhong W, Ahmad N. Role of sir-tuin histone deacetylase SIRT1 in prostate cancer. A target for prostate cancer management via its inhibition? *J Biol Chem* 2009; **284**: 3823-3832
- 94 **Hida Y**, Kubo Y, Murao K, Arase S. Strong expression of a longevity-related protein, SIRT1, in Bowen's disease. *Arch Dermatol Res* 2007; **299**: 103-106
- 95 **Jang KY**, Hwang SH, Kwon KS, Kim KR, Choi HN, Lee NR, Kwak JY, Park BH, Park HS, Chung MJ, Kang MJ, Lee DG, Kim HS, Shim H, Moon WS. SIRT1 expression is associated with poor prognosis of diffuse large B-cell lymphoma. *Am J Surg Pathol* 2008; **32**: 1523-1531
- 96 **Pruitt K**, Zinn RL, Ohm JE, McGarvey KM, Kang SH, Watkins DN, Herman JG, Baylin SB. Inhibition of SIRT1 reactivates silenced cancer genes without loss of promoter DNA hypermethylation. *PLoS Genet* 2006; **2**: e40
- 97 **Nosho K**, Shima K, Irahara N, Kure S, Firestein R, Baba Y, Toyoda S, Chen L, Hazra A, Giovannucci EL, Fuchs CS, Ogino S. SIRT1 histone deacetylase expression is associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer. *Mod Pathol* 2009; **22**: 922-932
- 98 **Song NY**, Surh YJ. Janus-faced role of SIRT1 in tumorigenesis. *Ann N Y Acad Sci* 2012; **1271**: 10-19
- 99 **Kriegel L**, Vieth M, Kirchner T, Menssen A. Up-regulation of c-MYC and SIRT1 expression correlates with malignant transformation in the serrated route to colorectal cancer. *Oncotarget* 2012; **3**: 1182-1193
- 100 **Lovaas JD**, Zhu L, Chiao CY, Byles V, Faller DV, Dai Y. SIRT1 enhances matrix metalloproteinase-2 expression and tumor cell invasion in prostate cancer cells. *Prostate* 2012 Oct 4; Epub ahead of print
- 101 **Xie M**, Liu M, He CS. SIRT1 regulates endothelial Notch signaling in lung cancer. *PLoS One* 2012; **7**: e45331
- 102 **Feng AN**, Zhang LH, Fan XS, Huang Q, Ye Q, Wu HY, Yang J. Expression of SIRT1 in gastric cardiac cancer and its clinicopathologic significance. *Int J Surg Pathol* 2011; **19**: 743-750

S- Editor Song XX L- Editor A E- Editor Xiong L